Active Ingredients: Ceftazidime (2000 mg) and Avibactam (500 mg)
Pharmaceutical Grade Excipients: Sterile, pyrogen-free diluent (WFI – Water for Injection)
Provides broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria
Effective in treating complicated intra-abdominal, urinary tract, and respiratory infections
Combines a third-generation cephalosporin with a β-lactamase inhibitor for enhanced efficacy
Restores the activity of ceftazidime against resistant bacterial strains
Demonstrates excellent safety and clinical success rates
Ceftazidime and Avibactam Injection 2.5 gm is a sterile, parenteral antibacterial combination used for the treatment of severe infections caused by Gram-negative bacteria, including resistant strains producing extended-spectrum β-lactamases (ESBLs) and carbapenemases.
Ceftazidime, a third-generation cephalosporin, inhibits bacterial cell wall synthesis, while Avibactam, a non-β-lactam β-lactamase inhibitor, protects Ceftazidime from enzymatic degradation. Together, they provide potent and broad antibacterial coverage.
This combination is indicated for hospital-acquired infections, intra-abdominal infections, and urinary tract infections in adult and pediatric patients. The formulation ensures consistent plasma levels and reliable clinical efficacy when administered intravenously.
Complicated intra-abdominal infections (cIAI)
Complicated urinary tract infections (cUTI), including pyelonephritis
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Infections caused by multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa
Adults: 2.5 gm (Ceftazidime 2 gm + Avibactam 0.5 gm) every 8 hours, administered by intravenous infusion over 2 hours
Dosage adjustment is required for patients with renal impairment
Use under the supervision of a qualified healthcare professional only
Explore our diverse range of pharmaceutical manufacturing categories, designed to deliver high-quality, reliable, and innovative healthcare solutions across multiple dosage forms.
Corporate Office
Plot No. :46 First Floor, Industrial Area Phase-2, Chandigarh-160002, India.
Manufacturing Unit
Village Kondi, Post Thana, District Solan, Baddi 173205 Himachal Pradesh, India.
